Clinical trial
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
NCT00480935 · University Health Network, Toronto, Other · Terminated
Key facts
| NCT number | NCT00480935 |
|---|---|
| Title | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma |
| Official title | A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Sunitinib Malate (Sutent) |
| Enrollment | 3 |
| Start date | Oct 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | May 31, 2007 |
| Last update posted | Dec 9, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: